Heart failure & cardiomyopathiesSecondary analysis
Impact of Baseline Kidney Dysfunction on Oral Diuretic Efficacy Following Hospitalization for Heart Failure – Insights from TRANSFORM-HF
- Secondary analysis of the TRANSFORM-HF randomised trial
- post-hoc analysis
Authors' conclusion
Among patients discharged after hospitalization for HF, there was no significant difference in clinical and patient-reported outcomes between torsemide and furosemide, irrespective of renal function.
Study context
- Population
- Patients hospitalized for heart failure (HF) across the spectrum of renal function (without dialysis)
- Participants
- 2,859 patients
- Comparison
- Torsemide vs furosemide, by baseline estimated glomerular filtration rate (eGFR)
- Primary endpoint
- Interaction between baseline eGFR category (<30, 30-<60, ≥60 ml/min/1.73 m²) and treatment effect on mortality and hospitalization outcomes and change in KCCQ-CSS
Primary result
As reported in the abstract
Treatment effect modification by baseline eGFR
- eGFR <30 ml/min/1.73 m²
- 336 (11.8%)
- eGFR 30-<60 ml/min/1.73 m²
- 1138 (39.8%)
- eGFR ≥60 ml/min/1.73 m²
- 1385 (48.4%)
- Baseline eGFR did not modify treatment effects on all-cause mortality, all-cause (re)-hospitalizations, components or composites (categorical or continuous eGFR)
- p-value for interaction all >0.108
- No treatment effect modification by eGFR for change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS)
- p-value for interaction all >0.052
Original publication
Impact of Baseline Kidney Dysfunction on Oral Diuretic Efficacy Following Hospitalization for Heart Failure – Insights from TRANSFORM-HF. Eur J Heart Fail. Published 1 April 2024. doi:10.1002/ejhf.3207
Summarised from the published abstract; every number is checked against it